Healthcare / Drug Manufacturers - Specialty & Generic
Exclusive insider sentiment analysis for the Drug Manufacturers - Specialty & Generic sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-10 10:04 | 2026-06-08 | INDV | Indivior Pharmaceuticals, Inc. | Preblick Ryan | Officer; Chief Financial Officer | Drug Manufacturers - Specialty & Generic | SALE | $37.70 | 36,000 | $1,357,200 | 284,751 | -11.2% |
| 2026-06-09 22:33 | 2026-06-05 | ANIP | ANI PHARMACEUTICALS INC | CAREY STEPHEN P. | Officer; SVP & CFO | Drug Manufacturers - Specialty & Generic | OPT+S | $80.00 | 3,312 | $264,960 | 180,393 | -1.8% |
| 2026-06-09 22:06 | 2026-06-08 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Drug Manufacturers - Specialty & Generic | OPT+S | $547.50 | 10,000 | $5,475,045 | 18,876 | -34.6% |
| 2026-06-09 21:40 | 2026-06-05 | NBIX | NEUROCRINE BIOSCIENCES INC | SHERWIN STEPHEN A | Director | Drug Manufacturers - Specialty & Generic | OPT+S | $165.32 | 25,000 | $4,132,970 | 15,860 | -61.2% |
| 2026-06-09 20:48 | 2026-06-08 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $547.49 | 9,500 | $5,201,109 | 40,513 | -19.0% |
| 2026-06-08 22:07 | 2026-06-04 | NBIX | NEUROCRINE BIOSCIENCES INC | Norwalk Leslie V | Director | Drug Manufacturers - Specialty & Generic | SALE | $168.06 | 1,250 | $210,072 | 2,838 | -30.6% |
| 2026-06-08 20:33 | 2026-06-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $547.62 | 9,500 | $5,202,437 | 40,513 | -19.0% |
| 2026-06-08 20:01 | 2026-06-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Francis Richard D | Officer; President and CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $34.35 | 6,153 | $211,356 | 1,177,529 | -0.5% |
| 2026-06-05 21:57 | 2026-06-04 | PCRX | Pacira BioSciences, Inc. | WILLIAMS KRISTEN | Officer; Chief Administrative Officer | Drug Manufacturers - Specialty & Generic | SALE | $22.27 | 10,259 | $228,468 | 167,062 | -5.8% |
| 2026-06-05 20:31 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $546.33 | 9,500 | $5,190,127 | 40,513 | -19.0% |
| 2026-06-05 20:31 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Drug Manufacturers - Specialty & Generic | OPT+S | $546.28 | 10,000 | $5,462,824 | 18,876 | -34.6% |
| 2026-06-04 22:02 | 2026-06-02 | NBIX | NEUROCRINE BIOSCIENCES INC | Cooke Julie | Officer; Chief Human Resources Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $156.22 | 36,937 | $5,770,235 | 22,374 | -62.3% |
| 2026-06-04 21:30 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer; EVP & GENERAL COUNSEL | Drug Manufacturers - Specialty & Generic | OPT+S | $547.07 | 8,300 | $4,540,643 | 45,172 | -15.5% |
| 2026-06-04 21:00 | 2026-06-04 | ALKS | Alkermes plc. | Gaffin David Joseph | Officer; EVP, CLO, Alkermes, Inc. | Drug Manufacturers - Specialty & Generic | SALE | $43.05 | 2,034 | $87,564 | 229,524 | -0.9% |
| 2026-06-04 20:30 | 2026-06-03 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $547.61 | 9,500 | $5,202,271 | 40,513 | -19.0% |
| 2026-06-04 20:00 | 2026-06-03 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Shields Matthew | Officer; EVP, Global Operations | Drug Manufacturers - Specialty & Generic | OPT+S | $32.87 | 16,195 | $532,330 | 9,989 | -61.9% |
| 2026-06-03 20:34 | 2026-06-02 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $538.39 | 9,500 | $5,114,742 | 40,513 | -19.0% |
| 2026-06-02 22:56 | 2026-05-29 | PAHC | PHIBRO ANIMAL HEALTH CORP | CORCORAN E THOMAS | Director | Drug Manufacturers - Specialty & Generic | BUY | $31.77 | 10,000 | $317,700 | 41,459 | +31.8% |
| 2026-06-02 22:08 | 2026-06-01 | NBIX | NEUROCRINE BIOSCIENCES INC | Onyia Jude | Officer; Chief Scientific Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $160.25 | 11,000 | $1,762,710 | 25,846 | -29.9% |
| 2026-06-02 22:03 | 2026-05-29 | NBIX | NEUROCRINE BIOSCIENCES INC | Delaet Ingrid | Officer; Chief Regulatory Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $156.71 | 2,261 | $354,321 | 16,225 | -12.2% |
| 2026-06-02 20:32 | 2026-05-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | SALE | $575.96 | 1,500 | $863,947 | 43,153 | -3.4% |
| 2026-06-02 20:33 | 2026-06-01 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Drug Manufacturers - Specialty & Generic | OPT+S | $547.87 | 10,000 | $5,478,663 | 18,876 | -34.6% |
| 2026-06-02 20:33 | 2026-06-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $547.91 | 9,500 | $5,205,104 | 40,513 | -19.0% |
| 2026-06-01 23:26 | 2026-06-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer; EVP R&D, Chief Medical Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $41.67 | 9,000 | $375,044 | 77,389 | -10.4% |
| 2026-06-01 20:31 | 2026-05-29 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $553.83 | 9,500 | $5,261,365 | 40,513 | -19.0% |
| 2026-05-29 20:37 | 2026-05-28 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $565.64 | 9,500 | $5,373,592 | 40,513 | -19.0% |
| 2026-05-29 22:09 | 2026-05-27 | NBIX | NEUROCRINE BIOSCIENCES INC | Onyia Jude | Officer; Chief Scientific Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $155.53 | 11,000 | $1,710,865 | 25,846 | -29.9% |
| 2026-05-29 22:03 | 2026-05-29 | ALKS | Alkermes plc. | Parisi Samuel Joseph | Officer; VP, Finance (Interim PAO) | Drug Manufacturers - Specialty & Generic | OPT+S | $42.36 | 16,217 | $687,007 | 7,717 | -67.8% |
| 2026-05-29 20:37 | 2026-05-28 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Drug Manufacturers - Specialty & Generic | OPT+S | $565.63 | 10,000 | $5,656,298 | 18,876 | -34.6% |
| 2026-05-29 20:16 | 2026-05-28 | ETON | Eton Pharmaceuticals, Inc. | BRYNJELSEN SEAN | Director, Officer; President & CEO | Drug Manufacturers - Specialty & Generic | SALE | $31.88 | 120,000 | $3,825,720 | 833,694 | -12.6% |
| 2026-05-28 22:08 | 2026-05-26 | NBIX | NEUROCRINE BIOSCIENCES INC | Boyer David W. | Officer; Chief Corp. Affairs Officer | Drug Manufacturers - Specialty & Generic | SALE | $156.64 | 3,888 | $609,023 | 7,799 | -33.3% |
| 2026-05-28 20:33 | 2026-05-27 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $575.40 | 9,500 | $5,466,283 | 40,513 | -19.0% |
| 2026-05-27 22:28 | 2026-05-22 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Officer; Chief Business Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $32.30 | 100,000 | $3,229,920 | 25,249 | -79.8% |
| 2026-05-27 20:30 | 2026-05-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | BUY | $575.96 | 1,500 | $863,947 | 43,153 | +3.6% |
| 2026-05-27 20:30 | 2026-05-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $572.38 | 8,000 | $4,579,018 | 40,513 | -16.5% |
| 2026-05-27 20:31 | 2026-05-26 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Drug Manufacturers - Specialty & Generic | OPT+S | $572.94 | 10,000 | $5,729,359 | 18,876 | -34.6% |
| 2026-05-26 20:30 | 2026-05-22 | MRMD | MARIMED INC. | Levine Jon R | Director, Officer, 10% owner; President and CEO | Drug Manufacturers - Specialty & Generic | BUY | $0.07 | 60,000 | $4,494 | 21,307,986 | +0.3% |
| 2026-05-26 23:54 | 2026-05-22 | GLASF | Glass House Brands Inc. | Tu William | Officer; SVP, Corporate Controller | Drug Manufacturers - Specialty & Generic | SALE | $10.29 | 15,837 | $162,952 | 0 | -100.0% |
| 2026-05-26 20:44 | 2026-05-22 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $567.74 | 9,500 | $5,393,559 | 40,513 | -19.0% |
| 2026-05-26 20:48 | 2026-05-26 | HIMS | Hims & Hers Health, Inc. | WELLS DAVID B | Director | Drug Manufacturers - Specialty & Generic | BUY | $24.24 | 48,400 | $1,172,974 | 224,417 | +27.5% |
| 2026-05-26 20:00 | 2026-05-21 | AMLX | Amylyx Pharmaceuticals, Inc. | Firestone Karen | Director | Drug Manufacturers - Specialty & Generic | BUY | $13.51 | 3,800 | $51,338 | 66,900 | +6.0% |
| 2026-05-22 23:00 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Mehta Vimal | Director, Officer; CEO and President | Drug Manufacturers - Specialty & Generic | OPT+S | $1.09 | 19,419 | $21,108 | 69,598 | -21.8% |
| 2026-05-22 23:01 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Steinhart Richard I | Officer; Chief Financial Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $1.09 | 6,845 | $7,427 | 26,300 | -20.7% |
| 2026-05-22 23:02 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Rodriguez Javier | Officer; See Remarks | Drug Manufacturers - Specialty & Generic | OPT+S | $1.08 | 6,560 | $7,111 | 26,803 | -19.7% |
| 2026-05-22 23:02 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Yocca Frank | Officer; Chief Scientific Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $1.09 | 6,845 | $7,427 | 26,175 | -20.7% |
| 2026-05-22 21:16 | 2026-05-21 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Drug Manufacturers - Specialty & Generic | OPT+S | $564.11 | 10,000 | $5,641,130 | 18,876 | -34.6% |
| 2026-05-22 20:46 | 2026-05-21 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $564.11 | 9,500 | $5,359,012 | 40,513 | -19.0% |
| 2026-05-21 21:49 | 2026-05-19 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Director | Drug Manufacturers - Specialty & Generic | OPT+S | $154.33 | 245,088 | $37,824,872 | 511,293 | -32.4% |
| 2026-05-21 21:08 | 2026-05-19 | INM | InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $1.54 | 468,551 | $721,569 | 800,000 | +141.4% |
| 2026-05-21 20:33 | 2026-05-21 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer; EVP & GENERAL COUNSEL | Drug Manufacturers - Specialty & Generic | OPT+S | $562.82 | 8,300 | $4,671,399 | 45,172 | -15.5% |
Strategic Analysis
Analyzing insider transactions within the Drug Manufacturers - Specialty & Generic sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.